The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors

MLA

Surrey M. Walton, et al. “The Effectiveness and Value of Emicizumab and Valoctocogene Roxaparvovec for the Management of Hemophilia A without Inhibitors.” Journal of Managed Care & Specialty Pharmacy, vol. 27, May 2021, pp. 667–73. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fbd014f52506ee45f88360eed7e385cb&authtype=sso&custid=ns315887.

APA

Surrey M. Walton, Steven D. Pearson, David Rind, Serina Herron-Smith, Danny Quach, & Foluso Agboola. (2021). The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors. Journal of Managed Care & Specialty Pharmacy, 27, 667–673.

Chicago

Surrey M. Walton, Steven D. Pearson, David Rind, Serina Herron-Smith, Danny Quach, and Foluso Agboola. 2021. “The Effectiveness and Value of Emicizumab and Valoctocogene Roxaparvovec for the Management of Hemophilia A without Inhibitors.” Journal of Managed Care & Specialty Pharmacy 27 (May): 667–73. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fbd014f52506ee45f88360eed7e385cb&authtype=sso&custid=ns315887.